BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18027149)

  • 1. Antiangiogenic agents in breast cancer.
    Salter JT; Miller KD
    Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
    [No Abstract]   [Full Text] [Related]  

  • 2. Breast tumour angiogenesis.
    Fox SB; Generali DG; Harris AL
    Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiogenesis and breast cancer].
    Bachelot T; Ray-Coquard I; Cassier P; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S203-10. PubMed ID: 17846006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab for advanced breast cancer.
    Traina TA; Rugo HS; Dickler M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in the treatment of breast cancer.
    Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
    Miller KD
    Breast Cancer Res; 2004; 6(3):128-32. PubMed ID: 15084233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Are antiangiogenic antibodies universal for solid tumor?].
    Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of angiogenesis by proteins, peptides and "small molecules"].
    Jayson G; Armand JP; Berdel WE
    Onkologie; 2005 Oct; 28 Suppl 4():29-34. PubMed ID: 16205103
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiogenesis of breast cancer.
    Schneider BP; Miller KD
    J Clin Oncol; 2005 Mar; 23(8):1782-90. PubMed ID: 15755986
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In focus: non-small cell lung cancer: E1505.
    Clin Adv Hematol Oncol; 2007 Mar; 5(3):206-8. PubMed ID: 17519882
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-angiogenic treatment and colorectal cancer].
    André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer.
    Banerjee S
    Steroids; 2011 Jul; 76(8):807-11. PubMed ID: 21439993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis as a strategic target for ovarian cancer therapy.
    Spannuth WA; Sood AK; Coleman RL
    Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Angiogenesis targeting in breast cancer].
    Fumoleau P; Coudert B; Mayer F; Isambert N; Favier L; Ferrant E
    Bull Cancer; 2007; 94(7 Suppl):F199-206. PubMed ID: 17964997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapy for cancer: current and emerging concepts.
    Jain RK
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.
    Ciccolini J; Benzekry S; Lacarelle B; Barbolosi D; Barlési F
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3453. PubMed ID: 26080431
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
    Bozza C; Fontanella C; Buoro V; Mansutti M; Aprile G
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):251-65. PubMed ID: 25597501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.